Skip to main content

Table 5 Association between receipt of guideline treatment and the probability of dying for cervical cancer patients (all stage groups) who were diagnosed 1984–2008 (n = 1085)

From: Effect of changes in treatment practice on survival for cervical cancer: results from a population-based study in Manitoba, Canada

  Any death Death from cervical cancer
No. of death/Total Adjusted HR (95 % CI)a p-value No. of death/Total Adjusted HR (95 % CI)a p-value
Tumour stage    <.0001    <.0001
 IAb 23/229 1.00   1/229 -  
 IB-IIA 139/398 3.47 (2.22–5.41)   80/398 1.00  
 IIB-IVA 261/406 8.38 (5.39–13.03)   185/406 3.13 (2.36–4.15)  
 IVB 50/52 68.09 (39.38–117.74)   46/52 25.60 (16.61–39.46)  
Age at diagnosis    <.0001    0.01
 0–45 127/518 1.00   99/518 1.00  
 46–65 165/333 1.69 (1.33–2.14)   106/333 1.12 (0.85–1.49)  
 >65 181/234 2.64 (2.07–3.37)   107/234 1.52 (1.14–2.03)  
Histology    0.47    0.08
 SCC 378/866 1.00   240/866 1.00  
 Others 95/219 1.09 (0.86–1.38)   72/219 1.28 (0.97–1.68)  
Area of residence    0.06    0.50
 Urban 292/707 1.00   196/707   
 Rural 181/378 1.20 (0.99–1.44)   116/378 1.08 (0.86–1.37)  
Time period*    0.0001    0.06
1984–1998 No receipt 35/124 1.00   25/124 1.00  
  Receipt 298/594 1.22 (0.85–1.75)   172/594 0.90 (0.59–1.39)  
1999–2008 No receipt 51/109 1.00   37/109 1.00  
  Receipt 89/258 0.44 (0.31–0.64)   78/258 0.51 (0.34–0.78)  
  1. HR hazard ratio, SCC squamous cell carcinoma/adenosquamous carcinoma, No receipt did not receive guideline treatment, Receipt Received guideline treatment
  2. *p-value for interaction between time period and treatment according to the guidelines
  3. aHR was adjusted for all variables shown in this table
  4. bHR for patients with tumour stage IA was not considered since none died from cervical cancer in the group who were not treated according to the guidelines